Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025.
During the fireside chat, Cue Biopharma will discuss program updates from the Immuno-STAT® platform including continued advancements in the development of CUE-401, the Company’s lead autoimmune asset.
Presentation Details
Cantor Global Healthcare Conference
Date: Friday, September 5, 2025
Time: 8:00 a.m. – 8:30 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Webcast Link:
A live and archived webcast of the fireside chat will be available under News and Events in the News and Publications section of the Company’s . The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information, please visit and follow us on and .
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
Media Contact
Jonathan Pappas
LifeSci Communications
